Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci.
The antistaphylococcal activity of LY146032 was tested in human pus in vitro and in a murine abscess model in vivo. The drug was not degraded by pus containing beta-lactamase and had equally good or better activity than nafcillin or vancomycin against Staphylococcus aureus or Staphylococcus epidermidis in vitro and in vivo. Its activity was slightly enhanced when used in combination with rifampin and tobramycin.
D000038:Abscess / Q000188:drug therapy* / Q000382:microbiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin; D006801:Humans; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects*; D013492:Suppuration / Q000188:drug therapy / Q000382:microbiology; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D010455:Peptides; D001618:beta-Lactamases; D017576:Daptomycin